American Capital Advisory LLC Buys 510 Shares of Johnson & Johnson (NYSE:JNJ)

American Capital Advisory LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 84.4% during the third quarter, HoldingsChannel reports. The firm owned 1,114 shares of the company’s stock after purchasing an additional 510 shares during the period. American Capital Advisory LLC’s holdings in Johnson & Johnson were worth $181,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Concurrent Investment Advisors LLC lifted its position in Johnson & Johnson by 8.9% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 101,736 shares of the company’s stock worth $16,487,000 after buying an additional 8,352 shares during the last quarter. Gordian Advisors LLC purchased a new stake in Johnson & Johnson during the third quarter valued at about $547,000. Umpqua Bank increased its holdings in shares of Johnson & Johnson by 2.3% in the third quarter. Umpqua Bank now owns 18,867 shares of the company’s stock worth $3,058,000 after buying an additional 423 shares during the period. Benchmark Financial Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Benchmark Financial Wealth Advisors LLC now owns 1,520 shares of the company’s stock valued at $246,000 after acquiring an additional 76 shares during the last quarter. Finally, Radnor Capital Management LLC bought a new position in Johnson & Johnson during the 3rd quarter worth approximately $9,318,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.4 %

Johnson & Johnson stock opened at $157.76 on Thursday. The business has a 50-day simple moving average of $162.96 and a two-hundred day simple moving average of $155.76. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market cap of $379.83 billion, a P/E ratio of 22.83, a P/E/G ratio of 2.81 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the company earned $2.66 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.14%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on JNJ. Citigroup boosted their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Royal Bank of Canada boosted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Wells Fargo & Company upped their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.